Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been ... Law firm ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

It cited avocados as an example. Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...

Philip Morris , Waste Management and Eli Lilly & Co were among the least shorted S&P 500 stocks at November end. As of Nov 30 ...